Proteomic analysis of hepatocellular carcinoma HepG2 cells treated with platycodin D

被引：7

作者：

LU JinJian ^{[1
]}

LU DeZhao ^{[2
]}

CHEN YuFei ^{[2
]}

DONG YaTing ^{[2
]}

ZHANG JunRen ^{[2
]}

LI Ting ^{[1
]}

TANG ZhengHai ^{[1
]}

YANG Zhen ^{[2
]}

机构：

[1] State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau

[2] College of Life Sciences, Zhejiang Chinese Medical University

来源：

Chinese Journal of Natural Medicines | 2015年 / 13卷 / 09期

关键词：

Platycodin D; HepG2; Proteome; 2-D DIGE;

D O I：

暂无

中图分类号：

R735.7 [肝肿瘤];

学科分类号：

100214 ;

摘要：

Platycodin D(PD), a triterpenoid saponin isolated from Platycodonis Radix, is a famous Chinese herbal medicine that has been shown to have anti-proliferative effects in several cancer cell lines. The aim of this study was to determine the changes in cellular proteins after the treatment of hepatocellular carcinoma HepG2 cells with PD using proteomics approaches. The cell viability was determined using the MTT assay. The proteome was analyzed by two-dimensional difference gel electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Western blot analysis was used to confirm the expression of changed proteins. Our results showed that PD inhibited the proliferation of HepG2 cells in concentration- and time-dependent manners. Sixteen proteins were identified to be up-regulated in PD-treated HepG2 cells, including ATP5 H, OXCT1, KRT9, CCDC40, ERP29, RCN1, ZNF175, HNRNPH1, HSP27, PA2G4, PHB, BANF1, TPM3, ECH1, LGALS1, and MYL6. Three proteins(i.e., RPS12, EMG1, and KRT1) decreased in HepG2 cells after treatment with PD. The changes in HSP27 and PHB were further confirmed by Western blotting. In conclusion, our results shed new lights on the mechanisms of action for the anti-cancer activity of PD.

引用

页码：673 / 679

页数：7

共 19 条

[1]

Platycodin D inhibits migration, invasion, and growth of MDA-MB-231 human breast cancer cells via suppression of EGFR-mediated Akt and MAPK pathways[J] . Jaemoo Chun,Yeong Shik Kim.Chemico-Biological Interactions . 2013

[2]

RPS12-specific shRNA inhibits the proliferation, migration of BGC823gastric cancer cells with S100A4 as a downstream effector[J] . Danqi Chen,Ruixiu Zhang,Wei Shen,Hao Fu,Shanshan Liu,Kailai Sun,Xiuju Sun.International Journal of Oncology . 2013 (5)

[3]

Platycodin D induces anoikis and caspase‐mediated apoptosis via p38 MAPK in AGS human gastric cancer cells[J] . Jaemoo Chun,Eun Ji Joo,Minseok Kang,Yeong Shik Kim.J. Cell. Biochem. . 2012 (2)

[4] Inhibiting ERp29 expression enhances radiosensitivity in human nasopharyngeal carcinoma cell lines [J].

Qi, Lin ;

Wu, Ping ;

Zhang, Xin ;

Qiu, Yuanzheng ;

Jiang, Weihong ;

Huang, Donghai ;

Liu, Yong ;

Tan, Pingqing ;

Tian, Yongquan .

MEDICAL ONCOLOGY, 2012, 29 (02) :721-728

[5]

Involvement of Prohibitin Upregulation in Abrin-Triggered Apoptosis[J] . Yu-Huei Liu,Konan Peck,Jung-Yaw Lin,Senthamil R. Selvan.Evidence-Based Complementary and Alternative Medicine . 2011

[6]

Platycodin D inhibits adipogenesis of 3T3‐L1 cells by modulating kruppel‐like factor 2 and peroxisome proliferator‐activated receptor γ[J] . HaeyongLee,RyunhwaKang,Yeong ShikKim,Sang‐InChung,YoosikYoon.Phytother. Res. . 2010 (S2)

[7] Proteomic analysis of anti-tumor effects by tetrandrine treatment in HepG2 cells [J].

Cheng, Zhixiang ;

Wang, Keming ;

Wei, Jia ;

Lu, Xiang ;

Liu, Baorui .

PHYTOMEDICINE, 2010, 17 (13) :1000-1005

[8] Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells [J].

Zhang, Daohai ;

Putti, Thomas C. .

EXPERIMENTAL CELL RESEARCH, 2010, 316 (20) :3522-3531

[9] Prohibitin physically interacts with MCM proteins and inhibits mammalian DNA replication [J].

Rizwani, Wasia ;

Alexandrow, Mark ;

Chellappan, Srikumar .

CELL CYCLE, 2009, 8 (10) :1621-1629

[10] Platycodin D2 is a potential less hemolytic saponin adjuvant eliciting Th1 and Th2 immune responses [J].

Xie, Yong ;

Deng, Wen ;

Sun, Hongxiang ;

Li, Duo .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2008, 8 (08) :1143-1150

← 1 2 →